loading
Precedente Chiudi:
$25.87
Aprire:
$25.88
Volume 24 ore:
185.92K
Relative Volume:
0.15
Capitalizzazione di mercato:
$1.72B
Reddito:
$5.79M
Utile/perdita netta:
$-199.61M
Rapporto P/E:
-8.603
EPS:
-3.01
Flusso di cassa netto:
$-188.48M
1 W Prestazione:
+1.09%
1M Prestazione:
+17.21%
6M Prestazione:
+53.59%
1 anno Prestazione:
-20.12%
Intervallo 1D:
Value
$25.59
$26.06
Intervallo di 1 settimana:
Value
$24.79
$26.46
Portata 52W:
Value
$14.40
$32.66

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name
Nome
Celldex Therapeutics Inc
Name
Telefono
908-200-7500
Name
Indirizzo
53 FRONTAGE ROAD, HAMPTON
Name
Dipendente
186
Name
Cinguettio
@search?q=celldex
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
CLDX's Discussions on Twitter

Confronta CLDX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CLDX
Celldex Therapeutics Inc
25.89 1.72B 5.79M -199.61M -188.48M -3.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
403.98 100.41B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.75 59.59B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
462.66 59.77B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
768.21 45.14B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
343.21 37.42B 3.81B -644.79M -669.77M -6.24

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-28 Iniziato Canaccord Genuity Buy
2025-03-20 Iniziato Morgan Stanley Overweight
2025-02-13 Iniziato UBS Buy
2024-10-07 Iniziato Citigroup Buy
2024-09-30 Iniziato Goldman Neutral
2024-09-27 Downgrade Wolfe Research Outperform → Peer Perform
2024-06-18 Iniziato Stifel Buy
2024-06-11 Iniziato Wolfe Research Outperform
2023-12-20 Iniziato TD Cowen Outperform
2023-11-10 Aggiornamento Wells Fargo Underweight → Equal Weight
2023-08-22 Iniziato Wells Fargo Underweight
2021-09-17 Iniziato Jefferies Buy
2021-09-10 Iniziato SVB Leerink Outperform
2021-07-22 Iniziato Guggenheim Buy
2020-02-21 Iniziato Cantor Fitzgerald Overweight
2017-08-01 Ripresa H.C. Wainwright Buy
2016-11-07 Iniziato Aegis Capital Buy
2016-03-08 Downgrade Jefferies Buy → Hold
2016-03-07 Downgrade Guggenheim Buy → Neutral
2016-03-07 Downgrade Leerink Partners Outperform → Mkt Perform
2016-03-07 Downgrade Wedbush Outperform → Neutral
2016-03-01 Iniziato H.C. Wainwright Buy
2015-08-11 Reiterato Brean Capital Buy
2015-08-11 Reiterato Oppenheimer Outperform
2015-08-11 Reiterato ROTH Capital Buy
2015-06-02 Reiterato WBB Securities Strong Buy
2014-11-17 Reiterato ROTH Capital Buy
2014-03-04 Reiterato Oppenheimer Outperform
2013-07-08 Reiterato Cantor Fitzgerald Buy
2013-03-08 Reiterato Cantor Fitzgerald Buy
2013-02-26 Reiterato Oppenheimer Outperform
2013-01-10 Reiterato Cantor Fitzgerald Buy
2012-10-02 Reiterato Oppenheimer Outperform
2012-09-14 Reiterato Cantor Fitzgerald Buy
Mostra tutto

Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie

pulisher
Sep 29, 2025

Will Celldex Therapeutics Inc. rebound enough to break evenWeekly Risk Summary & AI Enhanced Trading Signals - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Is Celldex Therapeutics Inc. reversing from oversold territory2025 Market Sentiment & Free Community Consensus Stock Picks - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

How interest rate cuts could boost Celldex Therapeutics Inc. stockFed Meeting & Fast Gain Stock Trading Tips - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Sep 29, 2025
pulisher
Sep 28, 2025

Analyzing Celldex Therapeutics Inc. with risk reward ratio charts2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com

Sep 28, 2025
pulisher
Sep 28, 2025

How moving averages guide Celldex Therapeutics Inc. tradingM&A Rumor & Long-Term Safe Return Strategies - newser.com

Sep 28, 2025
pulisher
Sep 27, 2025

Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cu... - ADVFN

Sep 27, 2025
pulisher
Sep 27, 2025

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat

Sep 27, 2025
pulisher
Sep 25, 2025

One Celldex Therapeutics Insider Raised Stake By 40% In Previous Year - 富途牛牛

Sep 25, 2025
pulisher
Sep 23, 2025

Sovran Advisors LLC Purchases New Shares in Celldex Therapeutics, Inc. $CLDX - MarketBeat

Sep 23, 2025
pulisher
Sep 22, 2025

Mirador Capital Partners LP Raises Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat

Sep 22, 2025
pulisher
Sep 21, 2025

Canaccord Genuity Group Reaffirms Buy Rating for Celldex Therapeutics (NASDAQ:CLDX) - MarketBeat

Sep 21, 2025
pulisher
Sep 21, 2025

Technical signs of recovery in Celldex Therapeutics Inc.July 2025 Final Week & Real-Time Stock Price Movement Reports - newser.com

Sep 21, 2025
pulisher
Sep 21, 2025

Why Celldex Therapeutics Inc. is moving todayWeekly Stock Analysis & Daily Stock Trend Reports - newser.com

Sep 21, 2025
pulisher
Sep 19, 2025

How correlated is Celldex Therapeutics Inc to the S P500Market Growth Report & Entry and Exit Point Strategies - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates - MSN

Sep 19, 2025
pulisher
Sep 19, 2025

Key resistance and support levels for Celldex Therapeutics Inc.2025 AllTime Highs & Consistent Return Investment Signals - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Shorts Report: Will Celldex Therapeutics Inc benefit from geopolitical trendsTrade Risk Assessment & Weekly Setup with High ROI Potential - khodrobank.com

Sep 19, 2025
pulisher
Sep 19, 2025

Celldex Therapeutics, Inc. $CLDX Stock Position Raised by Rhumbline Advisers - Defense World

Sep 19, 2025
pulisher
Sep 19, 2025

Is Celldex Therapeutics Inc. showing signs of accumulationQuarterly Portfolio Report & Target Return Focused Picks - newser.com

Sep 19, 2025
pulisher
Sep 18, 2025

Does Celldex Therapeutics Inc. show high probability of reboundGlobal Markets & Risk Controlled Daily Plans - newser.com

Sep 18, 2025
pulisher
Sep 18, 2025

Quarterly Earnings: Can Celldex Therapeutics Inc disrupt its industryJuly 2025 Institutional & Target Return Focused Stock Picks - خودرو بانک

Sep 18, 2025
pulisher
Sep 18, 2025

Momentum Shift: Will Celldex Therapeutics Inc benefit from government policyJuly 2025 Setups & Community Verified Swing Trade Signals - خودرو بانک

Sep 18, 2025
pulisher
Sep 18, 2025

Should you hold or exit Celldex Therapeutics Inc. nowChart Signals & Weekly Top Stock Performers List - newser.com

Sep 18, 2025
pulisher
Sep 18, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock potential in CSU market - Investing.com Nigeria

Sep 18, 2025
pulisher
Sep 18, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock potential in CSU market By Investing.com - Investing.com South Africa

Sep 18, 2025
pulisher
Sep 17, 2025

Celldex Presents Data Demonstrating Barzolvolimab Improves - GlobeNewswire

Sep 17, 2025
pulisher
Sep 17, 2025

Celldex reports strong efficacy for urticaria drug regardless of IgE levels - Investing.com Canada

Sep 17, 2025
pulisher
Sep 17, 2025

Celldex Therapeutics Says Barzolvolimab Data Shows Sustained Efficacy in Chronic Spontaneous Urticaria - MarketScreener

Sep 17, 2025
pulisher
Sep 17, 2025

What are WSFSs technical support levelsQuarterly Portfolio Review & Verified Entry Point Detection - خودرو بانک

Sep 17, 2025
pulisher
Sep 17, 2025

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 - GlobeNewswire

Sep 17, 2025
pulisher
Sep 17, 2025

71% Complete Response: Celldex's Novel CSU Drug Shows Breakthrough Results for All Patient Types - Stock Titan

Sep 17, 2025
pulisher
Sep 16, 2025

Growth Report: Can Celldex Therapeutics Inc disrupt its industryTrade Risk Assessment & AI Forecasted Stock Moves - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Published on: 2025-09-17 11:44:49 - khodrobank.com

Sep 16, 2025
pulisher
Sep 16, 2025

Woodline Partners LP Sells 825,586 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat

Sep 16, 2025
pulisher
Sep 16, 2025

Downgrade Watch: Will Celldex Therapeutics Inc benefit from geopolitical trendsWeekly Trend Report & Smart Swing Trading Techniques - خودرو بانک

Sep 16, 2025

Celldex Therapeutics Inc Azioni (CLDX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$35.84
price up icon 1.59%
$86.03
price up icon 1.44%
$31.46
price up icon 2.54%
$102.62
price up icon 4.05%
$145.06
price up icon 0.50%
biotechnology ONC
$343.40
price up icon 0.76%
Capitalizzazione:     |  Volume (24 ore):